Shanghai Pharmaceuticals released its third-quarter report: Industrial revenues continued to grow at a high rate

On October 30, Shanghai Pharmaceuticals released its third quarter 2017 report. Data show that in the third quarter, Shanghai Pharmaceuticals achieved operating income of 99,031 million yuan (RMB in RMB, the same as between 20), up 9.41% YoY, and achieved rapid growth in both industry and commerce. Net profit attributable to shareholders of listed companies was RMB2.689 billion, up 9.42% YoY, and the slowdown was mainly affected by the decline in the contribution profits of joint ventures. Excluding the decline in the contribution profits of joint and joint ventures, the net profit attributable to shareholders of listed companies increased by 14.26% YoY. Net income attributable to shareholders of listed companies, net of non-recurring gains and losses, was RMB2,456 million, up 7.59% YoY, and earnings per share was RMB0.9999. Net cash flow from operating activities was 1.846 billion yuan, up 40.93 percent year-on-year.
pharmaceutical industry, Shanghai Pharmaceuticals achieved operating income of 11.153 billion yuan in the first three quarters of 2017, up 18.70% YoY, while the industrial sector contributed 15.51% YoY. Industrial revenue remained high, with 60 key products achieving sales revenue of RMB5,864 million, up 12.16% YoY, accounting for 56.32% of industrial sales revenue, and the average gross margin of key products was 70.60%, up 1.62 percentage points from a year earlier. During the reporting period, Shanghai Pharmaceutical Research and Development Project achieved a number of phased results. 1 class of innovative drugs "SPH3348 API and its tablets" clinical trial application was accepted, therapeutic biologics 1 class of new drugs "injection recombinant anti-HER2 humanized monoclonal antibody composition" was approved clinically. He has won many awards in scientific research awards, including the "Top 10 Listed Companies in China's Most Innovative Pharmaceuticals 2017" by the China Pharmaceutical Enterprise Management Association, and the title of "Best Industrial Enterprise in China's Pharmaceutical Research and Development Product Line 2017" by the Ministry of Industry and Information Technology.
pharmaceutical business, operating income in the first three quarters was 87.878 billion yuan, up 8.33 percent year-on-year, and business sector contribution profit increased 11.38 percent year-on-year. The impact of the implementation of the two-vote system on the transfer business led to a slowdown in revenue growth, but limited impact on profits.
recently, Goldman Sachs, the world's leading investment bank, selected a list of 50 shares of the world's "long-term growth" in terms of sales, profit growth, market capitalisation and valuation levels, with Shanghai Pharmaceuticals among them. Shanghai Pharmaceuticals said this is the overseas capital market for the company's future development of affirmation. As a leading integrated industrial group in china, Shanghai Pharma will continue to adhere to intensive development, innovation and development, international development and combined development, further optimize research and development models and mechanisms, adhere to the key product focus strategy, strengthen academic marketing-oriented, professional marketing team and channel management team building, enhance product sales and market share, grasp the distribution industry integration opportunities, accelerate the landing of key mergers and acquisitions projects, continue to improve the national network layout and continue to focus on overseas asset acquisition opportunities. (Xinhuanet)